Telix Pharmaceuticals Limited (NASDAQ:TLX) is among the best Australian stocks to buy in 2026. Telix Pharmaceuticals Limited (NASDAQ:TLX) is using a combination of internal programs and partnership arrangements to expand its product portfolio. On April 21, the company announced that it plans to present clinical trial data for its prostate cancer drug candidate at the American Society of Clinical Oncology Annual Meeting. This event is planned for May 29 to June 2 in Chicago.
Pressmaster/Shutterstock.com
The presentation will focus on the safety and tolerability of TLX591-Tx based on the findings from Part 1 of the ProstACT Global Phase 3 study. The Part 1 trial assessed the safety, tolerability, biodistribution, and radiation dose profile of the drug candidate in patients with castration-resistant prostate cancer. Some 36 patients were enrolled for this trial. Part 2 trial targets around 490 patients with castration-resistant prostate cancer after prior treatment.
Telix Pharmaceuticals Limited has more than a dozen clinical trials underway worldwide. These include the trial of a potential brain cancer therapy. On April 14, Telix announced that the first patient had been dosed in the Phase 3 IPAX-BrIGHT trial of its brain cancer drug candidate TLX101-Tx. The company cast this as a milestone, noting that TLX101-Tx is the first radiopharmaceutical therapy for glioblastoma to enter Phase 3 development.
Away from internal efforts, Telix Pharmaceuticals Limited is also forging strategic partnerships. On April 13, the company announced a collaboration with Regeneron Pharmaceuticals to develop and commercialize radiopharmaceutical treatments for cancer patients. The companies agreed to share costs and profits. Telix Pharmaceuticals Limited said it could earn as much as $2.1 billion in milestone payments from this arrangement.
Telix Pharmaceuticals Limited (NASDAQ:TLX), based in Melbourne, Australia, is a global biopharmaceutical company. It develops radiopharmaceuticals products for cancer diagnosis and treatment. Its prostate cancer imaging agent has won regulatory approvals in Australia, the US, and Canada. The company’s pipeline features more than 18 ongoing clinical trials globally.
While we acknowledge the risk and potential of TLX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TLX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Falling Stocks to Invest In Now and 10 Best 52-Week High US Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
